Gene Therapy for ADA-SCID
Adenosine Deaminase Deficiency Severe Combined Immunodeficiency
PreclinicalResearch
Key Facts
Indication
Adenosine Deaminase Deficiency Severe Combined Immunodeficiency
Phase
Preclinical
Status
Research
Company
About Takara Bio
Takara Bio is a global biotechnology company with a mission to contribute to the advancement of life sciences and the improvement of human health. It has established itself as a key provider of research reagents, instruments, and contract development and manufacturing (CDMO) services, particularly in the fields of cell and gene therapy. The company's strategic direction focuses on expanding its therapeutic pipeline, scaling its CDMO capabilities, and deepening its research tools portfolio to address growing market demands in precision medicine.
View full company profile